Silver Book Fact

Aspirin use in AFib patients

Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients
reduced stroke risk by an average 22%.

Hart, RG, O Benavente, R McBride, and LA Pearce. Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation. Ann Intern Med. 1999; 131(7): 492-501. http://www.annals.org/content/131/7/492.1.full

Reference

Title
Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation
Publication
Ann Intern Med
Publication Date
1999
Authors
Hart, RG, O Benavente, R McBride, and LA Pearce
Volume & Issue
Volume 131, Issue 7
Pages
492-501
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.